Drugs / BCD-180
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05407779 | Jan 2021 → Sep 2023 | — | Biocad | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05445076 | Apr 2022 → Dec 2025 overdue | spondyloarthropathy | Biocad | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06333210 | Dec 2023 → Dec 2024 overdue | spondyloarthropathy | Biocad | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCD-180 | “The aim of the study is to evaluate the efficacy, safety, immunogenicity, pharmacokinetics and pharmacodynamics of two doses of study drug (BCD-180) in comparison with placebo...” NCT05445076 ↗ |
| Modality | Monoclonal antibody | “anti-TRBV9 monoclonal antibody single infusion at dose 1” NCT05407779 ↗ |
| Route | Intravenous | “single intravenous administration” NCT05407779 ↗ |
| Target | TRBV9 | “anti-TRBV9 monoclonal antibody single infusion at dose 1” NCT05407779 ↗ |